Informed prostate cancer risk-adjusted testing: a new paradigm.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23194122.
- Also identified by DOI 10.1111/j.1464-410X.2012.11621.x.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
• Currently there is significant confusion and polarisation about prostate cancer screening for both patients and physicians alike. • We propose a risk-adjusted testing programme, which would lead to fewer patients who need to be tested and treated to save a life and also eliminate inappropriate prostate-specific antigen testing in the elderly and patients with severe co-morbidities where there is no clear benefit.
Medical subject headings
- Early Detection of Cancer
- Mass Screening
- Prostate-Specific Antigen
- Prostatic Neoplasms